• New oncology assets to include proposed biosimilars for Trastuzumab/Hyaluronidase combination (Herceptin® SC/Herceptin HYLECTA™), Nivolumab (Opdivo®) and Pembrolizumab (Keytruda®)
  • Company to outline integration as a wholly owned subsidiary into Biocon Ltd., strengthening its global leadership in biosimilar insulins and GLP‑1 peptide generics to cover the full spectrum of diabetes care

BENGALURU : Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), will introduce three new oncology biosimilars, further strengthening its comprehensive cancer portfolio. The company will also highlight its plans to integrate as a wholly owned subsidiary of Biocon Limited and the vital role of biosimilars in expanding access to affordable medicines at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.

Oncology Portfolio

The company is set to unveil three new biosimilar oncology assets—Trastuzumab/Hyaluronidase (Herceptin® SC/Herceptin HYLECTA™), Nivolumab (Opdivo®), and Pembrolizumab (Keytruda®)—at the 2026 J.P. Morgan Healthcare Conference. With these new oncology assets, including two PD-1 inhibitors, Biocon Biologics will have one of the most comprehensive oncology portfolios in the industry. This will enable the company to broaden the availability of critical oncology therapies through cost‑effective biosimilar alternatives. Global sales of Keytruda were $29.5 billion in 2024; Opdivo sales in 2024 were $9.3 billion; and Herceptin SC and Herceptin HYLECTA combined sales were $1.72 billion in 2024. These new assets are among the largest oncology biologics scheduled to lose exclusivity over the next five years and will join Biocon Biologics’ existing portfolio of 17 oncology medications, which includes Pertuzumab (Perjeta®) that was recently submitted to the FDA, as well as several small molecule cancer therapies. The company’s oncology portfolio, including undisclosed products, represents an over $75 billion opportunity, or approximately 35% of the global oncology pharmaceutical market4.

Corporate Integration

Biocon Limited recently announced its plans to integrate Biocon Biologics as a wholly owned subsidiary. This integration marks a pivotal step in combining the businesses to leverage the global commercial infrastructure, simplifying the corporate structure and strengthening Biocon’s global position to lead in diabetes, oncology, and immunology — therapeutic areas that together account for nearly 40% of global pharmaceutical revenues. The integration, which is expected to be completed no later than March 31, 2026, will also uniquely position Biocon as the only company offering both biosimilar insulins and generics for complex peptides, including GLP-1s, to address the full spectrum of diabetes care. The integration will enhance Biocon Biologics’ ability to deliver innovative, affordable medicines to over 6 million patients in more than 120 markets worldwide. Post integration and upon requisite approvals, Shreehas Tambe will take on the role of CEO & Managing Director of the combined business.

Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd, said: “At the 2026 J.P. Morgan Healthcare Conference, we will share how our integration with Biocon Limited strengthens Biocon Biologics’ ability to deliver both biosimilars and generics at global scale. This will position us to better serve patients across diabetes, oncology, and immunology, including expanding access to biosimilar insulins and generic GLP‑1 peptides amid the rising diabetes and obesity burden. Guided by a science‑led, R&D approach, we are advancing a strong pipeline with 17 oncology assets to meet varied patient needs. These efforts underscore our commitment to providing affordable, high‑quality medicines for patients around the world.”

Shreehas Tambe will present at the J.P. Morgan Healthcare Conference (APAC Track) on Thursday, January 15, 2026 at 8:00 AM PST / 11 AM EST / 9:30 PM IST.  A live audio webcast and replay of the Biocon Biologics presentation at J.P. Morgan will be available online. The Company’s presentation will also be available in the investor relations section of its website, bioconbiologics.com, following the event. He will also participate in a fireside chat at the ENDPOINTS at JPM26 conference on Tuesday, January 13, 2026 titled, “Achieving the Promise of Biosimilars: Insights from Biocon Biologics CEO & MD Shreehas Tambe.”